News

Obesity drugs

Trevogrumab cut lean mass loss on semaglutide in a Lancet phase 2 trial. The three-drug version had safety problems

By Kareem Brown

Published · Updated

A vintage balance scale with brass pans on a glass shelf
Illustrative stock photo.

A Lancet trial published on November 11 tested whether an antibody drug can protect lean mass during semaglutide weight loss. It can, partly. Adults taking semaglutide plus trevogrumab lost less lean mass than adults taking semaglutide plus placebo. The trial did not show that this keeps people stronger or healthier.

The trial is COURAGE, a phase 2 study funded by Regeneron, which makes trevogrumab. It enrolled 975 adults with obesity at 60 US sites. Everyone took semaglutide, titrated to 2.4 mg weekly, plus placebo or trevogrumab, which blocks myostatin (GDF8).

What lean mass did on semaglutide alone

People on semaglutide plus placebo lost 6.6% of their lean mass over 26 weeks and 7.3% over 52 weeks. Lean mass measured this way includes muscle but also water and organs, so it is a proxy for muscle, not a direct count.

What trevogrumab changed

At 26 weeks, trevogrumab 200 mg reduced lean mass loss by 3.1 percentage points against placebo, and 400 mg by 2.7 points. At 52 weeks, the 75 mg dose reduced it by 3.1 points. The 25 mg dose did not differ clearly from placebo (1.5 points, with a confidence interval that crossed zero).

Trevogrumab alone did not significantly change total weight loss. On 400 mg, fat mass fell 3.4 percentage points more than on placebo. The 200 mg group and the 52-week doses showed no significant difference in fat mass or bodyweight, which is not proof that none exists.

The three-drug arm was the problem

One arm added garetosmab, which blocks activin A. It kept the most lean mass (4.5 points better than placebo) and the most extra fat loss. It also had serious adverse events in 14 of 149 people (9%), 48 discontinuations (32%) and muscle spasms in 41%. Both deaths were in this arm; the paper says a causal association was not identified.

What this means for someone on a GLP-1

For now, nothing you can buy. Trevogrumab is an experimental antibody, not available outside trials. The practical point is the baseline: on semaglutide alone, lean mass fell by roughly 7% in this trial. That is the loss people try to limit with resistance training and protein.

The authors say plainly that the next question is whether keeping lean mass preserves physical function and metabolic health. This trial did not report strength or function outcomes, so a bigger scan number should not be read as proof of a stronger body.

The limits

This is a single sponsor-funded phase 2 trial. Most authors report being Regeneron employees and shareholders. Follow-up was at most 52 weeks, and the trial reports changes in scans, not in what people could lift, climb or carry.

Sources (3)

This is news reporting and not medical advice.